Member Info for metis20

"Following a post-period end £5.75 million fundraising the business remains well capitalised with a £10.5 million net cash position as at the 30 April 2020."

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/AVCT/14529613.html

a little more detail
"The virus is captured from the patient's sample using beads that are coated with the Affirmer reagent. Those beads are deposited onto a glass slide that is put into the mass spectrometer.."

that link - replace asterisks by directors-talk-interviews but leave out the hyphens!

https://www.***************************/avacta-group-ceo-alastair-smith-discusses-covid-19-antigen-test-interview/412817915

Extract – "BAMS tests are very high performance because they combine that capture of the virus using very specific Affirmer reagents with the power of mass spectrometry to detect the virus. So the specificity and sensitivity of the BAMS test that we develop at Adeptrix should be very high indeed.

The other huge advantage is there is already a large installed base of these mass spectrometers around the world in hospitals and that is not currently being used for Covid 19 testing. So we will be bringing the testing power of all these machines into service by developing this kit."

2020 Bank Holiday May 8, 2020 Closed
2020 Bank Holiday May 25, 2020 Closed
https://www.tradinghours.com/exchanges/lse/market-holidays/2020

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/SLP/14519314.html

· Net profit of $25.4 million, a 123% increase quarter-on-quarter (Q2: $11.4 million)

https://www.dailymail.co.uk/news/article-8257233/Government-orders-50million-game-changing-immunity-tests.html

https://avacta.com/avacta-ceo-alastair-smith-provides-update-on-covid-19-collaboration-with-cytiva/

from final slide at around 5:15 mins

"Avacta and Cytiva will develop the test, clinically validate it and obtain regulatory approvals required to make it commercially available to healthcare professionals and consumers as quickly as possible during the summer."

https://sonanano.com/lateral-flow/ lots to study here!

https://avacta.com/diagnostics/ more info about affirmers being used in diagnosis -

Diagnostics
Affimer® reagents are ideal tools for use in a wide variety of diagnostic applications.
Affimer® reagents are ideal tools for use in a wide variety of diagnostic and research applications. With a rapid development timeline Affimer® reagents represent a quick solution to rapidly unfolding research needs and ever growing needs for quality diagnostic reagents with consistent supplies. Custom Affimer solutions are available to meet your Diagnostic and Research needs.

Affimer® technology offers highly specific target recognition in a variety of complex samples, while retaining both chemical and thermal stability. Affimer® molecules offer flexibility in formatting via both genetic and chemical means. A single strategic cysteine residue addition allows for site specific functionalisation with enzymes, dyes, fluors, or immobilization onto a variety of surfaces. In addition to classical chemical methods of modification, we are also able to express genetic modifications to optimise performance (GFP, carrier proteins, and even multimers).

We develop highly specific, reproducible, and stable tools for use in point of care (POC) tests, ligand binding assays and bioprocessing and separations from complex matrices.

Lateral flow devices, commonly referred to as LFDs, use immunoassay technology via a combination of antibodies, nitrocellulose membranes and coloured nanoparticles in order to produce visually interpreted results. In addition to using antibodies aptamers, affirmers or other novel reagents can be incorporated. Lateral flow devices can also be combined with reader technology to produce rapid fully quantitative results.

Above from https://www.abingdonhealth.com/articles/importance-lateral-flow-rapid-tests-diagnostics/

So yes affirmers are used in diagnostic tests

Meeting to seek approval for the placings is tomorrow

"The Fundraising is, amongst other things, subject to Shareholder approval of Resolution 1, which will be proposed at the General Meeting."
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/AVCT/14492014.html

A circular including notice of the General Meeting (the "Circular") will be sent to Shareholders later today convening the General Meeting to be held at 10:00 a.m. on 23 April 2020. Details of the General Meeting, as well as form of proxy will be sent to shareholders with the Circular. The Circular will also be available on the Company's website, www.avacta.com once posted.

https://avacta.com/wp-content/uploads/2020/04/258649-Project-Wreath-NOA-Letter-Web.pdf

It is the date for announcing the financial results that has been moved forward

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, today announces that, due to the timing of the General Meeting and completion of the proposed Admission of both the Placing Shares and Subscription Shares on 23 April 2020, it will now announce its financial results for the 17 months ended 31 December 2019 on Wednesday, 6 May 2020.
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/AVCT/14505709.html

Q1 2020 trading update – staggering!

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PLUS/14493925.html

Q1 2020 revenue $316.6 - so even higher than the previous record quarterly revenue (Q1 2018) of $297.3. That was at the height of the cryptocurrency bubble.

Q1 2020 EBITDA of $231.6 – as compared to $237.3 for Q1 2018

(FY2019 EBITDA was only $191)

Less than 3 weeks ago the sp had sunk to around 62p...

From today's RNS

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/BGO/14490214.html

Ray Anderson, Executive Chair and co-founder at Bango, said: "This is one of the most exciting milestones in the history of Bango. NHN is a hugely successful data, marketing and payments business based in South Korea, one of the most technologically advanced countries in the world. NHN has a fantastic growth story and a history of first-mover innovation which, coupled with the existing data platform know-how at Audiens, will enable us to create a powerful force for technology leadership in online commerce".

"Together we will create a global leader in data technology", said Mr. Lee, Director of NHN Corp. "The NHN strategy is to partner with global leaders to take our research and technology to the world. We are privileged to enter into this strategic partnership with Bango, which has built a unique position at the heart of global mobile commerce for the 21st century".

"The partnership with NHN began last year with the inclusion of NHN data in Bango Marketplace and is now accelerating through this investment by NHN in Audiens," said Paul Larbey, Bango CEO. "This deeper relationship underlines the Bango vision of becoming the technology behind every payment choice. I am delighted to welcome this highly successful data technology leader as both a majority shareholder in Audiens and as a strategic investor in Bango".

again - over 2% over a couple of hours

https://www.kitco.com/market/

https://uk.investing.com/commodities/real-time-futures

https://www.kitco.com/charts/rhodium.html

approx 54% of 3E revenue is currently down to Rhodium

https://liberum.com/videos/sylvania-platinum/ (published yesterday)

Five short videos - second of these –

How much of a challenge is the power situation in South Africa?

- end of that clip - "I think our exposure at the moment is not that significant"

Easier to read version (!) - Points from today's Investor Presentation re challenge #3

Currently fresh current arisings and ROM fines emanating from mining operations constitute
approximately 40% - 45% of SDO’s total plant feed, but it is anticipated that only a relatively small part of this total capacity will be impacted by the downturn;

o Sylvania has the necessary resources, flexibility and infrastructure to increase dump mining, albeit at slightly lower PGM grades, to supplement any potential current arisings or ROM fines shortfall and to maintain consistent feed to the plants;

o Management is in continuous discussions with host mines in order to manage impact and evaluate potential processing alternatives that could benefit both Sylvania and our hosts;

o Sylvania remain confident to deliver on guided production target of 74,000oz to 76,000oz for FY2020

Points from today's Investor Presentation re challenge #3

Currently fresh current arisings and ROM fines emanating from mining operations constitute
approximately 40% - 45% of SDO’s total plant feed, but it is anticipated that only a relatively small part
of this total capacity will be impacted by the downturn;
o Sylvania has the necessary resources, flexibility and infrastructure to increase dump mining, albeit at slightly lower
PGM grades, to supplement any potential current arisings or ROM fines shortfall and to maintain consistent feed to
the plants;
o Management is in continuous discussions with host mines in order to manage impact and evaluate potential
processing alternatives that could benefit both Sylvania and our hosts;
o Sylvania remain confident to deliver on guided production target of 74,000oz to 76,000oz for FY2020.